Richard A Scolyer
Richard A Scolyer
Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital
Verified email at - Homepage
Cited by
Cited by
Genomic classification of cutaneous melanoma
R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ...
Cell 161 (7), 1681-1696, 2015
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
GV Long, AM Menzies, AM Nagrial, LE Haydu, AL Hamilton, GJ Mann, ...
Journal of Clinical Oncology 29 (10), 1239-1246, 2011
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
Cutaneous melanoma
JF Thompson, RA Scolyer, RF Kefford
The Lancet 365 (9460), 687-701, 2005
Pathology and genetics of skin tumours
PE LeBoit
IARC, 2006
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma
CG Lian, Y Xu, C Ceol, F Wu, A Larson, K Dresser, W Xu, L Tan, Y Hu, ...
Cell 150 (6), 1135-1146, 2012
Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 1-8, 2012
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
JS Wilmott, GV Long, JR Howle, LE Haydu, RN Sharma, JF Thompson, ...
Clinical cancer research 18 (5), 1386-1394, 2012
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma
F Azimi, RA Scolyer, P Rumcheva, M Moncrieff, R Murali, SW McCarthy, ...
Journal of clinical oncology 30 (21), 2678-2683, 2012
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ...
The Lancet Oncology 19 (5), 672-681, 2018
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center
MF Azzola, HM Shaw, JF Thompson, S Soong, RA Scolyer, GF Watson, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
AM Menzies, LE Haydu, L Visintin, MS Carlino, JR Howle, JF Thompson, ...
Clinical cancer research 18 (12), 3242-3249, 2012
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ...
Clinical cancer research 20 (7), 1965-1977, 2014
The system can't perform the operation now. Try again later.
Articles 1–20